Of note, spinal cord high-grade astrocytomas could be treated with targeted therapies; indeed, BRAF alteration status was demonstrated to be present in about 80% of low-grade spinal cord astrocytomas and these cases could be considered for a therapeutic approach with BRAF-MEK inhibitors. Here, BRAF is linked to astrocytoma (excluding glioblastoma).